ALPS Group Inc Ordinary Share (ALPS) carries a Roarable Rating of D (Sell) with 50/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, ALPS Group Inc Ordinary Share (NASDAQ: ALPS) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 50/100 at a spot price of $0.33 (+0.03% 1D, market cap $54.1M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, ALPS ranks #300 in composite RQD confidence.
Within the Health Care sector (Medical/Nursing Services), ALPS carries a Roarable D (50/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, EUDA (EUDA Health Holdings Limited) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $46.4M) and BMGL (Basel Medical Group Ltd) posts a D+ grade (53/100 RQD, P/E N/A, ROIC —, cap $36.0M). Among the 5-stock peer group, ALPS leads on earnings multiple (N/A) while EUDA leads on capital efficiency (-35.0% ROIC).
For ALPS Group Inc Ordinary Share (ALPS), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #300 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
SEC XBRL Trailing 12 Months: 0% FCF Margin ($1.5M FCF) & 52% Gross Margin
Macro rate sensitivity & RSI-14 (27.4) create a -12 pt regime headwind
While ALPS currently carries a cautious 50/100 (D) rating due to Macro Regime Fit (8/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.37) and Max Pain ($0.35) forces dealer call-delta covering toward $3.04.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
ALPS Group Inc Ordinary Share (ALPS) advanced +0.03% to $0.33, trading at 4% of its 52-week range ($0.23 – $2.9). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
KUALA LUMPUR, Malaysia, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (“Alps” or “the Company”) (Nasdaq: ALPS), an integrated biotechnology platform headquartered in Malaysia, today announced that its shareholders app
Alps Group Inc ("Alps" or "the Company") (NASDAQ:ALPS), an integrated biotechnology platform headquartered in Malaysia, today announced that its shareholders approved, in accordance with Cayman Islands
Revenue Grew 44% to $4.9 Million, Led by Continued Growth Across Cellular Therapy, Medical Testing, Laboratory and Aesthetics Beauty Services, and Healthcare Products Began Trading on the Nasdaq Global Market Under the T
Agreement Marks Company’s Expansion into Precision Oncology Testing, with the Goal of Establishing Malaysia's First Clinically Validated PDO PlatformKUALA LUMPUR, Malaysia, June 23, 2026 (GLOBE NEWSWIRE) -- Alps Group In
MyGenome Joins a Limited Number of Southeast Asian Laboratories Delivering WGS Under Internationally Recognized Clinical Standards, Strengthening its Position in Southeast Asian GenomicsKUALA LUMPUR, Malaysia, June 09, 2
KUALA LUMPUR, Malaysia, May 19, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (the “Company” or “Alps Group”), the parent company of Alps Life Sciences Inc. (“Alps Holdco”), a fully integrated biotechnology research and health
KUALA LUMPUR, Malaysia, April 17, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (the “Company” or “Alps Group”), the parent company of Alps Life Sciences Inc. (“Alps Holdco”), a biotechnology research and healthcare platform f
KUALA LUMPUR, Malaysia, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (the “Company” or “Alps Group”), the parent company of Alps Life Sciences Inc. (“Alps Holdco”), a fully integrated biotechnology research and healt
KUALA LUMPUR, Malaysia, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (the “Company” or “Alps Group”), the parent company of Alps Life Sciences Inc. (“Alps Holdco”), a fully integrated biotechnology research and healt
KUALA LUMPUR, Malaysia, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (NASDAQ: ALPS) (the “Company” or “Alps Group”), a fully integrated biotechnology research and healthcare platform specializing in predictive, preve
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ALPS today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ALPS. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, ALPS Group Inc Ordinary Share (ALPS) ranks #300 by composite RQD confidence (50/100, grade D) and #739 by equity capitalization ($54.1M). Within this direct 5-issuer industry benchmark cohort, ALPS leads on earnings valuation at N/A trailing P/E, while EUDA leads on capital efficiency and profitability with -35.0% ROIC and 43.9% gross margin. BMGL currently holds the highest overall quantitative score in the immediate peer group at 53/100 (D+) compared with ALPS at 50/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ALPS
ACTIVE
ALPS Group Inc Ordinary Share | D | 50/100 | — | — | — | +0.03% | $54.1M | Benchmark Subject |
| EUDA EUDA Health Holdings Limited | D- | 35/100 | — | 43.9% | -35.0% | +14.19% | $46.4M | /euda-vs-alps → |
| BMGL Basel Medical Group Ltd | D+ | 53/100 | — | — | — | +6.11% | $36.0M | /bmgl-vs-alps → |
| PIII P3 Health Partners Inc. (Class A) | E | 24/100 | — | — | -35.0% | -4.05% | $30.5M | /piii-vs-alps → |
| DCGO DocGo Inc. | D- | 41/100 | — | — | -35.0% | -9.59% | $27.0M | /dcgo-vs-alps → |
ALPS Group Inc Ordinary Share (ALPS) operates in Medical/Nursing Services (Health Care) with an equity capitalization of $54.1M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.
As of 2026-11-02, ALPS Group Inc Ordinary Share (NASDAQ: ALPS) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 50/100 at a spot price of $0.33 (+0.03% 1D, market cap $54.1M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, ALPS ranks #300 in composite RQD confidence.
Within the Health Care sector (Medical/Nursing Services), ALPS carries a Roarable D (50/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, EUDA (EUDA Health Holdings Limited) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $46.4M) and BMGL (Basel Medical Group Ltd) posts a D+ grade (53/100 RQD, P/E N/A, ROIC —, cap $36.0M). Among the 5-stock peer group, ALPS leads on earnings multiple (N/A) while EUDA leads on capital efficiency (-35.0% ROIC).
For ALPS Group Inc Ordinary Share (ALPS), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #300 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
ALPS last traded at $0.33 (+0.03% on volume of 36,187 shares), positioning the stock -10.81% below its 50-day simple moving average ($0.37) and -51.47% below its 200-day simple moving average ($0.68). Across its 52-week range of $0.23 to $2.90, ALPS sits at the 3.7% percentile with a 14-day RSI of 27.4 (OVERSOLD (<32)) and an implied next-earnings move of ±8.7% ($1.00 to $0.36).
Why ALPS Stock Traded Steady Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, ALPS scores 50 out of 100, grade D, labeled "Roarable Sell — Underperform / Distribution Warning." The five pillars are: Fundamental Cash Engine 12/20 (ROIC 0%; FCF yield 0%); Whale 13F Flow 8/20 (institutional accumulation and options positioning); Insider Conviction 9/20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit 8/20 (Beta 1.0; sector sensitivity); and Forensic Balance Sheet 13/20 (Altman Z 2.5; Piotroski F 6/9; Debt/Equity 0.5).
For a prospective investor, the cash-engine pillar is the weakest signal in the source data: a reported 0% ROIC and 0% FCF yield mean the rating does not credit the business with generating returns on capital or free cash flow. The forensic pillar is comparatively stronger, with an Altman Z of 2.5 and a Piotroski F of 6/9 cited in the rating, but these are balance-sheet and accounting-quality indicators rather than evidence of earnings power. Flow and insider pillars score modestly, indicating limited sponsorship signals in the rating inputs. The overall verdict points to distribution-warning conditions rather than an upside-driver profile. Valuation tradeoffs cannot be evaluated against earnings, since P/E and EPS are not available in source data.
Real-time company headlines, analyst actions, and sector developments for ALPS Group Inc Ordinary Share (ALPS) • Click "Debate This Headline" to argue it in the Roar Pit below
KUALA LUMPUR, Malaysia, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (“Alps” or “the Company”) (Nasdaq: ALPS), an integrated biotechnology platform headquartered in Malaysia, today announced that its shareholders app
Alps Group Inc ("Alps" or "the Company") (NASDAQ:ALPS), an integrated biotechnology platform headquartered in Malaysia, today announced that its shareholders approved, in accordance with Cayman Islands
Revenue Grew 44% to $4.9 Million, Led by Continued Growth Across Cellular Therapy, Medical Testing, Laboratory and Aesthetics Beauty Services, and Healthcare Products Began Trading on the Nasdaq Global Market Under the T
Agreement Marks Company’s Expansion into Precision Oncology Testing, with the Goal of Establishing Malaysia's First Clinically Validated PDO PlatformKUALA LUMPUR, Malaysia, June 23, 2026 (GLOBE NEWSWIRE) -- Alps Group In
MyGenome Joins a Limited Number of Southeast Asian Laboratories Delivering WGS Under Internationally Recognized Clinical Standards, Strengthening its Position in Southeast Asian GenomicsKUALA LUMPUR, Malaysia, June 09, 2
KUALA LUMPUR, Malaysia, May 19, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (the “Company” or “Alps Group”), the parent company of Alps Life Sciences Inc. (“Alps Holdco”), a fully integrated biotechnology research and health
KUALA LUMPUR, Malaysia, April 17, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (the “Company” or “Alps Group”), the parent company of Alps Life Sciences Inc. (“Alps Holdco”), a biotechnology research and healthcare platform f
KUALA LUMPUR, Malaysia, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (the “Company” or “Alps Group”), the parent company of Alps Life Sciences Inc. (“Alps Holdco”), a fully integrated biotechnology research and healt
Welcome to the ALPS (ALPS Group Inc Ordinary Share) Roar Pit. Current RQD Composite is 50/100 (Roarable Sell — Underperform / Distribution Warning) in Medical/Nursing Services. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on ALPS, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless ALPS Group Inc Ordinary Share expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on ALPS, the market is fixating on short-term headline noise in Medical/Nursing Services and ignoring the balance sheet and cash flow trajectory. At $0.32 (52-wk range $0.23 - $2.90), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).